Thomas F. Miller Ph.D. (Chief Operating Officer) Windtree Therapeutics, Inc. (formerly Discovery Laboratories) is an American company which was set up in 1992 and now is based in Warrington, Pennsylvania, developing drug products (pulmonary medicine) for patients with respiratory disease.
The company joined an alliance with Laboratorios del Dr. Esteve, S.A.[1] In 2016, Discovery Laboratories changed name to Windtree Therapeutics, Inc.[2] The major products of the company are Surfaxin (based on its capillary aerosol-generating technology) and Aerosurf.
Aerosurf is a drug-device combination to prevent respiratory distress syndrome (RDS) in premature infants.
The phase II consists of two steps to evaluate the safety and tolerability of the drug and determine the optimal dose for premature infants with respiratory distress syndrome (RDS)[4] In October 2013, Discovery Laboratories received the agreement of updating Surfaxin (lucinactant) Intratracheal Suspension from the U.S. Food and Drug Administration (FDA) to prevent respiratory distress syndrome (RDS) in premature infants.
[5] In September 2012, Discovery Laboratories started the four research projects to explore the KL4 surfactant technology for acute lung injury (ALI).